| INTRODUC TI ON
Newly developed or recurrent hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication with oral direct-acting antiviral agents (DAA) has currently become a matter of debate in the hepatology community. After two different studies showed an unexpected high rate of HCC occurrence and recurrence after HCV eradication with DAA, 1,2 a huge amount of data has been presented on this issue
with conflicting results, making the question a big controversy. The most recent literature seems to deny a correlation between antiviral therapy and a higher risk of liver cancer. Kanwal et al 3 showed that HCV eradication is associated with a significant reduction in the risk of subsequent HCC development, which remains, however, 1.82%/y, thus justifying the need of continuous surveillance every 6 months in cirrhotic patients who achieve a sustained virological response (SVR). Similarly, Ioannou et al 4 found a 71% reduction risk in HCV patients eradicated with DAA with an annual incidence of HCC of 1.97%; risk remains relatively high (3.25%/y) in cirrhotic patients with virological failure to treatment.
Several studies have investigated the risk factors associated with HCC onset in patients achieving SVR with interferon (IFN)-based regimens. Diabetes, low albumin levels, low platelet count, advanced age and high alcohol consumption have all been associated with higher risk of HCC in patients who attained SVR. [5] [6] [7] Less data exist, however, in patients in whom HCV was eradicated with DAAs. A Japanese study including 954 patients treated with both triple therapy or all-oral antiviral therapy showed that advanced liver fibrosis and BMI >23 kg/m 2 were independently correlated with hepatocarcinogenesis. 8 In the study by Conti et al, 2 Child-Pugh class, liver fibrosis and a previous history of HCC were all associated with an increased risk of liver cancer.
Alpha-fetoprotein (AFP) is widely used as a serological marker in patients at risk of HCC, although its diagnostic sensitivity is rather low, being serum levels elevated only in 60% of patients with HCC. Moreover, an elevation of serum AFP can be observed also in patients with chronic HCV infection without HCC and has been associated with abnormal transaminases, advanced fibrosis and high model for end-stage liver disease (MELD) scores. 10, 11 Changes in AFP levels during IFN treatment have also been investigated. Two Japanese studies showed that an AFP reduction below 10 ng/mL after end of treatment (EOT) was associated with a lower subsequent risk of developing HCC. 12, 13 To our knowledge, little data exist about the predictive role of serum AFP in the setting of antiviral treatment with DAA. In a recently published study, a significant decrease in AFP levels was observed in cirrhotic patients achieving SVR with DAA, likely due to a reduction in liver inflammation. 14 This suggests that in HCV-eradicated patients, persistently elevated AFP levels might be a more specific predictor of HCC.
The aim of this study was therefore to investigate HCC occurrence and recurrence in a large cohort of HCV-infected cirrhotic patients who completed a full treatment course with DAA, identifying eventual risk factors for cancer development. We focused particularly on AFP trend during treatment in order to evaluate its predictive power after HCV eradication. 
| MATERIAL S AND ME THODS

Key points
• Hepatitis C virus-infected cirrhotic patients maintain a substantial residual risk of HCC even after treatment with DAA.
• The risk of HCC is much greater in patients who had a history of successfully treated HCC prior to treatment with DAA.
• Lack of reduction in AFP levels during treatment and even slightly elevated serum AFP levels at EOT are independently associated with a greater risk of either recurrent or occurrent HCC. 
| RE SULTS
The demographic, clinical, virological and biochemical characteristics of the 1045 patients included in the study are summarized in Alpha-fetoprotein values were assayed at baseline and at EOT:
in the vast majority of patients (85.8%), AFP levels decreased after treatment, the mean levels falling from 16.1 ± 36.2 ng/mL at baseline to 11.4 ± 55.0 ng/mL at EOT, respectively (P = 0.006). Reduction in AFP levels during treatment remained statistically significant in patient without a previous history of HCC (P < 0.000 01) but not in those with a previous HCC (P = 0.24; Figure 1 ).
No relation was observed between the entity of decrease in AFP levels (ΔAFP) and the subsequent development of HCC (P 0.26).
During the study period (the current median follow-up after reaching EOT is 17.3 ± 7.2 months), 95 patients (9.9%) had an incident HCC. As expected, incidence was higher in patients with recurrent (41 of 102, 39%) than occurrent tumours (54 of 943, 5.7%).
Number, size, vascular invasion and type of treatment of newly diagnosed HCC are summarized in Table 2 . In patients who already had a history of HCC, the type of treatment refers to the recurrent HCC.
Median time from EOT to HCC diagnosis was 9.6 and 8.1 months for occurrent and recurrent HCC, respectively (P = 0.26). The majority of patients (56.8%) presented with a single focal lesion; the average diameter of the largest neoplastic lesion was 21.8 ± 13.1 mm.
Only five patients presented with vascular invasion at diagnosis and extrahepatic tumour spread was not observed. Eighty-three percentage of patients were within Milan criteria, and 56.3% achieved curative treatments. According to Kaplan-Meier curves ( Figure S1 ), the 12-month incidence rates were 4.4% and 28.7 % for de novo and recurrent HCC, respectively (log rank; P = 0.000 01).
At univariate analysis, patients who developed an incident HCC during the study period were older (P = 0.005), had more frequently a history of previous HCC (<0.000 01), presented with a more advanced disease with higher MELD score (P = 0.0002), more prolonged INR (P = 0.02), a higher total bilirubin (P = 0.01) and a lower platelet count (P = 0.03); moreover, they presented significantly lower rates of SVR (P < 0.000 01). Finally, in patients who developed a subsequent HCC, we observed higher levels of AFP both at baseline and at EOT (P = 0.000 06 and P < 0.000 01, respectively) and a higher rate of AFP level >6 ng/mL at EOT; they also had reduction in AFP levels during treatment much less frequently compared to patients who did not develop HCC. Other previously suggested risk factors such as high body mass index or male gender failed to show any association with the development of HCC. In addition, HCV viral load, HCV genotype and the DAA regimen were also unrelated to the occurrence of HCC. Figure 2 shows the Kaplan-Meier estimates of the incidence of HCC according to the reduction in AFP levels during treatment with DAA. Patients without reduction in AFP levels during treatment had a higher risk of HCC development (P = 0.001). Moreover, patients who maintain AFP levels >6 ng/mL at EOT had a much greater incidence of HCC compared to those with AFP ≤6 ng/mL (P = 0.0002, Figure 3) .
A multivariable logistic regression analysis was performed in order to assess the independent predictors of HCC development after EOT. All the variables found to have a significant association, or even a trend, with HCC formation at univariate analysis, was tested in the logistic regression analysis. In the final model, only three variables emerged as significant independent predictors of HCC formation after EOT: a history of previous HCC (P < 0.000 01, OR:
10.76, 95% CI: 5.89-19.34), platelet count at baseline (P = 0.009, OR 0.99 CI: 0.99-1.00) and lack of reduction in AFP levels during treatment with DAA (P = 0.0005, OR: 2.98, CI: 1.60-5.54; Table 3 ). The present study included a large multicentre cohort of consecutive HCV-infected cirrhotic patients who completed a treatment course with DAA. The study cohort comprised a subgroup of patients (9.8%) who had a previous history of HCC and were tumourfree when starting treatment. SVR rates were high (95.6%) and did not differ between patients with or without a previous history of HCC (P = 0.35), a finding well in keeping with available data in the cirrhotic population. 20 This result is even more impressive considering that almost one in five patients received a therapy with sofosbuvir alone, which is now considered as suboptimal.
| D ISCUSS I ON
During a median follow-up of 17.3 months after EOT, 95 patients (9.9%) developed HCC. This figure is consistently higher than that observed in cirrhotic patients who achieved SVR and even higher than in those with ongoing HCV infection. 21 Notably, HCC incidence rates differ significantly between patients who achieved SVR and those who relapsed after EOT (P < 0.000 001), as already shown by after ALT normalization, were more prone to develop HCC in the follow-up. Interestingly, in this study, the authors found that an AFP cut-off value as low as 6 ng/mL had the greatest sensitivity in predicting HCC occurrence. We sought here to investigate the predictive role of AFP measured at EOT in HCV-infected cirrhotic patients treated with DAA, when HCV-induced liver inflammation had presumably been blunted, thus no longer behaving as a potential confounder. As clearly shown by the Kaplan-Meier curves, the risk of developing HCC was remarkably higher in patients with AFP levels above 6 ng/mL compared to those with AFP ≤6 ng/ mL, and this was already found after the initial months after EOT.
Notably, this occurred both in patients with and without a previous history of HCC. The curves were also similar after excluding patients with virological failure, in whom inflammation due to persistent virological activity could influence AFP levels. Therefore, as already reported in the HBV setting, the simple determination of AFP levels in HCV-infected cirrhotic patients at completion of a DAA treatment course allows to identify a subgroup of patients at greater risk of cancer, characterized by only minimally elevated AFP. It is tempting to speculate that these patients may require a more strict surveillance for HCC than currently recommended.
Our study has several limitations. First, more data, hopefully from controlled studies, are needed to judge the actual risk of developing HCC in patients who achieve HCV eradication with DAA, and a longer period of follow-up would definitely be necessary to draw definitive conclusions. Second, likewise the other available reports, our study missed a control group, which does not exclude the possibility of a patient selection bias. Indeed, the current availability of safe, easy-to-use and potent DAAs allows to treat with IFN-free short schedules patients who were untreatable until recently, who might be intrinsically more prone to develop cancer. Third, understanding the carcinogenesis process in this setting would certainly require specific studies collecting pathological and immunological data to investigate tumour biology and the alterations in the immune system occurring after the abrupt HCV elimination.
In conclusion, in this multicentre study of a large cohort of HCV-infected cirrhotic patients who complete a DAA treatment course, the residual risk of HCC was substantial, regardless that the vast majority of patients attained SVR. Lack of reduction in AFP levels during treatment, platelet count at baseline and a history of previous HCC were significant and independent predictors of early HCC development. Moreover, persistence of even minimally elevated AFP levels at EOT might represent an additional risk factor.
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